Rameda (RMDA) has announced its earnings, as well as began commercial production of Molnupiravir medicine.
Rameda’s Earnings📈
The company reported a net profit of EGP 180.1 million in 2021, up 61.5% YoY.
The company’s revenues rose to EGP 1.25 billion, compared to EGP 960.17 million in 2020.
More on Molnupiravir
Molnupiravir is an oral medicine developed by “Merck” after receiving the necessary authorizations from the Egyptian Drug Authority (EDA), US Food and Drug Administration (USFDA) & UK’s Medicines & Healthcare Products Regulatory Agency (MHRA).
The company plans to release the first batch of “Molnupiravir” before the end of Q1 of this year at a price of EGP 625 per pack that contains 40 capsules.
